Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.68 |
| ▸ | CES1 | P23141 | 1/20 | 0.68 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | PLG | P00747 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.57 |
| ▸ | KLK1 | P06870 | 1/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891571 | 0.93 | CES2 (0.59) | CES2CES1F2PLGPLAU | |
| SCHEMBL2883914 | 0.84 | ALDH1A1 (0.68) | CES2CES1F2PLGPLAU | |
| SCHEMBL12551372 | 0.82 | CES2 (0.68) | CES2CES1F2PLGPLAU | |
| SCHEMBL30250451 | 0.81 | CES2 (0.74) | CES2CES1F2PLGPLAU | |
| SCHEMBL941698 | 0.81 | CES2 (0.74) | CES2CES1F2PLGPLAU | |
| SCHEMBL31032483 | 0.81 | CES2 (1.00) | CES2CES1F2PLGPLAU | |
| SCHEMBL29613672 | 0.81 | CES2 (0.74) | CES2CES1F2PLGPLAU | |
| SCHEMBL7220072 | 0.81 | CES2 (1.00) | CES2CES1F2PLGPLAU | |
| SCHEMBL2887371 | 0.81 | ALDH1A1 (0.55) | CES2CES1F2PLGPLAU | |
| SCHEMBL2837486 | 0.80 | CES2 (0.65) | CES2CES1F2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309319-B2 | Fluorescent probe for measurement of UDP-glucuronosyltransferase | THE UNIVERSITY OF TOKYO (JP) | 2012-11-13 | — | — | US | claimed |
| US-20100297681-A1 | FLUORESCENT PROBE FOR MEASUREMENT OF GLUCURONATE TRANSFERASE | THE UNIVERSITY OF TOKYO (JP) | 2010-11-25 | — | — | US | claimed |
| EP-1984325-A2 | SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2008-10-29 | — | — | EP | claimed |
| US-20080045598-A1 | Novel sulfonanilide analogs as selective aromatase modulators (SAMs) | THE OHIO STATE UNIVERSITY (US) | 2008-02-21 | — | — | US | claimed |
| WO-2007120379-A2 | SULFONANILIDE ANALOGS AS SELECTIVE AROMATASE MODULATORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-10-25 | — | — | WO | claimed |
| US-6936173-B2 | Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration | NEOSE TECHNOLOGIES, INC. (US) | 2005-08-30 | — | — | US | claimed |
| US-20030029799-A1 | Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration | NEOSE TECHNOLOGIES | 2003-02-13 | — | — | US | claimed |
| US-20020148791-A1 | Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration | NEOSE TECHNOLOGIES (US) | 2002-10-17 | — | — | US | claimed |
| JP-2001502005-A | — | — | 2001-02-13 | — | — | JP | claimed |
| CN-1242776-A | Carbohybrate purification using ultrafiltration, reverse osmosis and nanofiltration | NIOTH TECH CO LTD (US) | 2000-01-26 | — | — | CN | claimed |
| EP-0931097-A4 | CARBOHYDRATE PURIFICATION USING ULTRAFILTRATION, REVERSE OSMOSIS AND NANOFILTRATION | CYTEL CORP (US) | 2000-01-12 | — | — | EP | claimed |
| EP-0931097-A1 | CARBOHYDRATE PURIFICATION USING ULTRAFILTRATION, REVERSE OSMOSIS AND NANOFILTRATION | CYTEL CORPORATION (US) | 1999-07-28 | — | — | EP | claimed |
| WO-1998015581-A1 | CARBOHYDRATE PURIFICATION USING ULTRAFILTRATION, REVERSE OSMOSIS AND NANOFILTRATION | CYTEL CORPORATION (US) | 1998-04-16 | — | — | WO | claimed |
| US-5425942-A | Giant protein complex; useful in screening for cancer | OTSUKA PHARAMCEUTICAL CO., LTD. (JP) | 1995-06-20 | — | — | US | claimed |
| US-5120746-A | Inhibit gastric acid secretion | TOYAMA CHEMICAL CO., LTD. (JP) | 1992-06-09 | — | — | US | claimed |
| EP-0345750-A2 | Polyfunctional protease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-12-13 | — | — | EP | claimed |
| US-4643849-A | ANTIULCER, ANTISECRETORY AGENTS | TOYAMA CHEMICAL CO., LTD. (JP) | 1987-02-17 | — | — | US | claimed |
| WO-2024150815-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | 田辺三菱製薬株式会社 | 2024-07-18 | — | — | WO | disclosed |
| US-4082761-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS | THE UPJOHN COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4054585-A | FUNGICIDES, INSECTICIDES | UNIROYAL, INC. (US) | 1977-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045598-A1 | Novel sulfonanilide analogs as selective aromatase modulators (SAMs) | CYP19A1, AR, SULT2A1 | CES2 313/4885CES1 173/4885F2 4232/4885 |
| US-20020148791-A1 | Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration | OSTC, TREH, MGAM | CES2 522/4885CES1 1284/4885F2 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.